Compare IRS & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
IRSA Inversiones Y Representaciones S.A. Global Depositary Shares (Each representing ten shares of)
Current Price
Current Price
| Metric | IRS | WVE |
|---|---|---|
| Founded | 1943 | 2012 |
| Country | Argentina | Singapore |
| Employees | 1392 | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | 1994 | 2015 |
| Metric | IRS | WVE |
|---|---|---|
| Price | $15.47 | $16.01 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 15 |
| Target Price | N/A | ★ $27.53 |
| AVG Volume (30 Days) | 174.5K | ★ 12.9M |
| Earning Date | 11-06-2025 | 11-10-2025 |
| Dividend Yield | ★ 9.10% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.42 | N/A |
| Revenue | ★ $370,153,377.00 | $109,230,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $31.09 |
| P/E Ratio | $3.38 | ★ N/A |
| Revenue Growth | N/A | ★ 103.75 |
| 52 Week Low | $10.61 | $5.28 |
| 52 Week High | $17.29 | $21.73 |
| Indicator | IRS | WVE |
|---|---|---|
| Relative Strength Index (RSI) | 55.56 | 65.75 |
| Support Level | $14.80 | $6.93 |
| Resistance Level | $15.77 | $21.73 |
| Average True Range (ATR) | 0.61 | 1.51 |
| MACD | -0.08 | 1.14 |
| Stochastic Oscillator | 83.24 | 61.45 |
IRSA Inversiones y Representaciones SA is engaged in a diversified business. The company's operating segments include Shopping Malls, which comprise lease and service revenues principally related to the rental of commercial and other spaces in the company's shopping malls; Offices, which include lease revenues and other service revenues related to office activities; Sales and Developments, which include the development, maintenance, and sales of undeveloped parcels of land and/or trading properties; Hotels, which mainly include revenues from rooms, catering, and restaurants; and others. The company generates the majority of its revenue from the Shopping Malls segment.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.